Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
77.73
+0.72 (+0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
48
49
Next >
QQQ And QQQM ETFs Top Gainers And Laggards Of 2023
December 20, 2023
This article will look at the top gainers and laggards of the two popular ETFs, which have over $17 billion and $223 billion assets, respectively. The two funds are similar, with the only difference...
Via
Talk Markets
Topics
ETFs
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 19, 2023
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy...
Via
Benzinga
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?
December 19, 2023
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the
Via
Benzinga
(GILD) - Analyzing Gilead Sciences's Short Interest
December 18, 2023
Via
Benzinga
A Look Into Gilead Sciences Inc's Price Over Earnings
December 07, 2023
Via
Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today
December 06, 2023
Via
Benzinga
Why Is Compugen (CGEN) Stock Up 189% Today?
December 19, 2023
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.
Via
InvestorPlace
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
December 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy.
December 16, 2023
Lilly's weight loss drug appears to be on the way to becoming a megablockbuster.
Via
The Motley Fool
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
December 15, 2023
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.
Via
InvestorPlace
Looking Into Gilead Sciences's Recent Short Interest
November 22, 2023
Via
Benzinga
NASDAQ:GILD is probably undervalued for the fundamentals it is displaying.
December 12, 2023
Investors should take notice ofGILEAD SCIENCES INC (NASDAQ:GILD)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street
December 12, 2023
There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock.
Via
The Motley Fool
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
December 11, 2023
Via
Benzinga
Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions
December 11, 2023
Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion...
Via
Benzinga
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
December 10, 2023
Regulators are already on the case, and their findings will have financial impacts.
Via
The Motley Fool
3 biotech powerhouses poised to thrive amid sector rebound
December 08, 2023
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.
Via
MarketBeat
Topics
ETFs
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
December 07, 2023
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
Via
SBWire
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
December 07, 2023
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.
Via
InvestorPlace
3 Biotech Stocks That Could Be Multibaggers in the Making
November 30, 2023
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.
Via
InvestorPlace
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
November 30, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
November 30, 2023
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
Via
The Motley Fool
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
November 29, 2023
Tuesday, the FDA said it received reports of patients developing T-cell malig
Via
Benzinga
Exposures
Product Safety
J&J, Gilead, BMS: A look at undervalued dividend payers
November 29, 2023
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown
Via
MarketBeat
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
November 26, 2023
There's no time like the present to buy these stocks.
Via
The Motley Fool
Stocks Stall On November 21, 2023, As Systematic Flows Abate
November 21, 2023
Stocks finished the day lower by roughly 20 bps, which is not a big deal, as rates fell somewhat and the dollar rallied
Via
Talk Markets
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.